sumatriptan has been researched along with Idiopathic Parkinson Disease in 3 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using [3H]sumatriptan as a radioligand, 5-hydroxytryptamine (5-HT)1B receptors were examined in posterior striatum and midbrain post-mortem tissue sections of 12 patients who had died from representative degenerative movement disorders as compared to nine controls." | 3.70 | 5-HT1B receptor binding in degenerative movement disorders. ( Berciano, J; Castro, ME; Figols, J; Pascual, J; Pazos, A; Romón, T, 1998) |
| "Sumatriptan was injected subcutaneously in 10 de novo parkinsonian patients (aged 58-69 years) and in 9 age-matched normal controls." | 1.30 | Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. ( Boni, S; Caffarra, P; Chiodera, P; Coiro, V; Saginario, A; Scaglioni, A; Volpi, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benedetti, F | 1 |
| Pollo, A | 1 |
| Lopiano, L | 1 |
| Lanotte, M | 1 |
| Vighetti, S | 1 |
| Rainero, I | 1 |
| Volpi, R | 1 |
| Caffarra, P | 1 |
| Scaglioni, A | 1 |
| Boni, S | 1 |
| Saginario, A | 1 |
| Chiodera, P | 1 |
| Coiro, V | 1 |
| Castro, ME | 1 |
| Pascual, J | 1 |
| Romón, T | 1 |
| Berciano, J | 1 |
| Figols, J | 1 |
| Pazos, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo Effect in Children With Attention Deficit Disorder and/or Hyperactivity Disorder[NCT04766580] | 44 participants (Anticipated) | Interventional | 2021-02-17 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sumatriptan and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses.
Topics: Aged; Analgesia; Attitude to Health; Cognition; Conditioning, Operant; Consciousness; Female; Human | 2003 |
2 other studies available for sumatriptan and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease.
Topics: Aged; Analysis of Variance; Arginine; Case-Control Studies; Growth Hormone-Releasing Hormone; Human | 1997 |
5-HT1B receptor binding in degenerative movement disorders.
Topics: Aged; Aged, 80 and over; Corpus Striatum; Female; Humans; Huntington Disease; Male; Middle Aged; Mov | 1998 |